Septerna Inc. (SEPN)
NASDAQ: SEPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SEPN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.84B
- EPS (TTM)
- -$1.30
- Dividend yield
- None
- 52-week range
- 22.78 – 53.34
- Day range
- 38.23 – 39.89
- Volume / Avg
- 374.25K / 383.96K
- Beta
- —
- Shares outstanding
- 47.55M
52-week range
SEPN stock today
Septerna (SEPN) closed at $38.61 on Nov 20, down 1.51% (-$0.59), versus the S&P 500's 3.70% decline. At this level, SEPN sits in the middle of its 52-week range of $22.78 to $53.34: 27.6% below the high, set on Nov 11, 2026 and 69.5% above the low. SEPN is up 38.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 51.1%.
Septerna has posted a net loss over the last twelve months (EPS of -$1.30), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Septerna
Company profileSepterna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jeffrey T. Finer M.D., Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 134
- IPO year
- 2024
- Website
- septerna.com
Financial highlights
Full financialsIn fiscal 2025, Septerna generated $46.0 million in revenue, up 4174.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Septerna reported a net loss of $48.9 million, compared with a loss of $71.8 million a year earlier. Operating margin was -148.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $45.95M | $1.07M | $151.00K |
| Growth | +4174.51% | +611.92% | — |
| Net income | $-48.88M | $-71.80M | $4.18M |
| EPS (diluted) | $-1.10 | $-7.26 | $0.29 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$59.22+53.38%
- Strong buy 1
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.57 vs $-0.55
- Surprise
- -3.64%
SEPN news
All SEPN news- Septerna Reports Q3 Results; Advances SEP-479 And SEP-204 Toward Phase 1 Milestones In 2027NasdaqSEPN, BIO.B
- Septerna, Inc. GAAP EPS of -$0.57, revenue of $18.88MSeeking Alpha
- Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Moderna (MRNA) Q3 Earnings and Revenues Top EstimatesNasdaqMRNA, SEPN
- Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual MeetingGlobeNewswire
Septerna peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BHVNBiohaven Ltd. | 12.39 | -9.23% | $1.87B | vs SEPN |
| IMNMImmunome Inc. | 15.69 | -5.54% | $1.85B | vs SEPN |
| VERAVera Therapeutics Inc. Class A | 25.45 | -4.86% | $1.84B | vs SEPN |
| TRVITrevi Therapeutics Inc. | 13.35 | -2.70% | $1.90B | vs SEPN |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 6.98 | -2.92% | $1.81B | vs SEPN |
| HRMYHarmony Biosciences Holdings Inc. | 32.59 | -1.18% | $1.91B | vs SEPN |
| ZYMEZymeworks Inc. | 26.14 | -2.68% | $1.81B | vs SEPN |
| AUPHAurinia Pharmaceuticals Inc | 14.70 | -1.28% | $1.97B | vs SEPN |
Indexes, lists and sector
Septerna stock FAQ
What is Septerna's stock price today?
SEPN last traded at $38.61 as of Nov 20, 4:00 PM EST, down 1.51% on the day. Prices are delayed at least 15 minutes.
Who is Septerna's CEO?
Dr. Jeffrey T. Finer M.D., Ph.D. is the chief executive officer of Septerna Inc., which has about 134 employees.
What is the SEPN 52-week high?
The 52-week high for SEPN is $53.34 and the 52-week low is $22.78. The stock is currently 27.6% below its high.